)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Castle Biosciences
Castle Biosciences (CSTL) investor relations material
Castle Biosciences Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary30 Jul, 2026
Executive summary
Q2 2026 revenue reached $103.5 million, up 20% year-over-year, driven by strong growth in core test volumes, especially TissueCypher, while DecisionDx-Melanoma also grew and DecisionDx-SCC volumes declined due to Medicare coverage loss.
Full-year 2026 revenue guidance was raised to $365–$375 million from $345–$355 million, reflecting continued momentum and strong performance.
Positive adjusted EBITDA is expected for Q3, Q4, and full year 2026, supported by robust cash reserves and ongoing investments in commercial resources, evidence generation, and pipeline expansion.
AdvanceAD-Tx received NYSDOH approval, won a Genomics Innovation Award, and was validated for atopic dermatitis, expanding access and clinical impact.
Independent studies and regulatory milestones, including FDA Breakthrough Device Designation and multicenter validation for DecisionDx-Melanoma, highlighted clinical innovation.
Financial highlights
Q2 2026 revenue: $103.5 million (+20% YoY); gross margin: 74.9–75%; adjusted gross margin: 76.3%; adjusted EBITDA: $12.4 million.
Net loss for Q2 2026 was $2.1 million (diluted loss per share: $0.07), compared to net income of $4.5 million in Q2 2025, due to higher operating expenses and lower dermatologic test revenues.
Operating expenses rose to $106.6 million, with increases in sales, marketing, G&A, and R&D.
Net cash provided by operating activities was $15.2 million for Q2; cash, equivalents, and marketable securities totaled $266.8 million at quarter end.
Total test volume for Q2 2026 was 30,822.
Outlook and guidance
2026 revenue guidance raised to $365–$375 million, reflecting strong Q2 and expected continued growth.
Adjusted gross margin for 2026 expected in the low to mid-70s percent range.
Positive adjusted EBITDA anticipated for Q3, Q4, and full year 2026, as well as for 2027 barring strategic changes.
TissueCypher test volume expected to grow 50–52% for 2026; DecisionDx-Melanoma on track for mid to high single-digit volume growth.
Existing liquidity is expected to fund operations for at least the next 12 months.
DecisionDx-Melanoma vs MIA nomogram results
DecisionDx-SCC Medicare coverage change impact
DETECT-AD study goals for atopic dermatitis
DecisionDx-SCC Medicare coverage appeal status
Update on SciBase collaboration and technology
AdvanceAD-Tx commercial expansion timeline
Update on Novitas LCD for DecisionDx-SCC
Strategy for capturing the $33B AdvanceAD-Tx TAM
Timeline for reaching Adjusted EBITDA positivity
Multi-product model impact on melanoma growth
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Castle Biosciences
- Q2 2026 saw 32% core test volume growth, $103.5M revenue, and raised annual guidance.CSTL
Corporate presentation31 Jul 2026 - Q3 2024 revenue up 39% to $85.8M, guidance raised on strong test adoption and profitability.CSTLQ3 20248 Jul 2026
- Q1 revenue up 21%, guidance raised, Previse acquired, IDgenetix discontinued, SCC risk remains.CSTLQ1 20258 Jul 2026
- Q2 revenue up 74% to $87M; guidance raised to $275–300M on strong growth and margin gains.CSTLQ2 20248 Jul 2026
- Raised 2026 guidance after strong Q1 growth and expanded diagnostic test adoption.CSTLJefferies Global Healthcare Conference 20263 Jun 2026
- Q1 2026 revenue hit $83.7M, core test volumes rose 36%, and guidance increased to $345–355M.CSTLQ1 20267 May 2026
- Strong clinical evidence and financial growth support expansion and pipeline innovation.CSTLCorporate presentation6 May 2026
- Genomic testing enables precise SLNB decisions and improved melanoma outcomes.CSTLStatus update29 Apr 2026
- 2025 saw record revenue, strong governance, and enhanced compensation and ESG policies.CSTLProxy filing8 Apr 2026
Next Castle Biosciences earnings date
Canaccord Genuity's 46th Annual Growth Conference12 Aug, 2026
Castle Biosciences
Next Castle Biosciences earnings date
Canaccord Genuity's 46th Annual Growth Conference12 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage